The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer
- Fergus J. Couch1,2,
- Michele R. Johnson1,
- Kari G. Rabe3,
- Kieran Brune4,
- Mariza de Andrade3,
- Michael Goggins4,5,6,
- Heidi Rothenmund7,
- Steven Gallinger7,
- Alison Klein4,5,
- Gloria M. Petersen3 and
- Ralph H. Hruban4,5
- Departments of 1Laboratory Medicine and Pathology, 2Biochemistry and Molecular Biology, and 3Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota; Departments of 4Pathology, 5Oncology, and 6Medicine, The Sol Goldman Center for Pancreatic Cancer Research, The Johns Hopkins Medical Institutions, Baltimore, Maryland; and 7Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
- Requests for reprints:
Fergus J. Couch, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-3623; Fax: 507-266-0824. E-mail: couch.fergus{at}mayo.edu
Abstract
Mutations in the BRCA2 gene have been implicated in pancreatic cancer susceptibility through studies of high-risk breast and ovarian cancer families. To determine the contribution of mutations in BRCA2 to familial pancreatic cancer, we screened affected probands from 151 high-risk families identified through pancreatic cancer clinics for germ-line BRCA2 mutations. Of these families, 118 had two or more first- and second-degree relatives with pancreatic cancer, and an additional 33 had two or more affected second-degree relatives. The average age of onset for pancreatic cancer was 62.8 years. Five BRCA2 truncating mutations were identified, three in families with two or more first- and second-degree relatives with pancreatic cancer. Three of the families with mutations had a history of breast cancer but not ovarian cancer. Four of five families with mutations were identified through probands with early-onset (<55 years) pancreatic cancer. The results of this study were combined with those from a BRCA2 mutation study of 29 other families from the same Johns Hopkins University National Familial Pancreatic Tumor Registry to estimate the frequency of BRCA2 mutations. A total of 10 carriers from 180 families were identified, suggesting that BRCA2 mutations account for 6% of moderate and high-risk pancreatic cancer families. (Cancer Epidemiol Biomarkers Prev 2007;16(2):342–6)
Footnotes
-
↵9 http://www.myriadtests.com/provider/brca-mutation-prevalence.htm.
-
Grant support: NIH Specialized Programs in Research Excellence grants in pancreatic cancer CA102701 (G.M. Petersen, F.J. Couch, and M. de Andrade) and gastrointestinal malignancies CA62924 (K. Brune, M. Goggins, A. Klein, and R.H. Hruban) and R01 CA97075 (G.M Petersen) and the Ontario Cancer Research Network grant 02-NOV-02470CRN (S. Gallinger).
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted December 13, 2006.
- Received September 15, 2006.
- Revision received November 29, 2006.










